[Aldosterone antagonist therapy for chronic heart failure].
Yamamoto
Takeshi
T
Yano
Masafumi
M
D000450:Aldosterone / Q000096:biosynthesis / Q000502:physiology; D002908:Chronic Disease; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004232:Diuretics / Q000627:therapeutic use; D000077545:Eplerenone; D005355:Fibrosis / Q000209:etiology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009206:Myocardium / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use; D000077786:Torsemide; D020257:Ventricular Remodeling
D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D013449:Sulfonamides; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D000077786:Torsemide